Method of producing quinoline derivatives or their pharmaceutically acceptable salts of acids

专利摘要:
Compounds of the formula: wherein A stands for the radical -(CH2)2- which may bear one or two defined substituents; R1 stands for a (3-4C)alkyl or cyclopropyl radical, or a phenyl radical which may optionally bear one or two defined substituents, or a heteroaryl radical of five or six ring atoms which may optionally bear a (1-3C)alkyl substituent; R2 and R3 stand for hydrogen or a (1-2C)alkyl radical, or R2 stands for a (2-4C)alkylene radical which is linked to one of the carbon atoms forming the two-carbon-atom-backbone of A so as to form, together with the adjacent nitrogen atom, a pyrrolidinyl or piperidyl radical; and one of R4 and R5 stands for hydrogen, and the other stands for hydrogen, a halogen atom or a (1-3C)alkyl or (1-3C)alkoxy radical; and acid-addition salts thereof. Processes for the manufacture of said compounds. Pharmaceutical compositions comprising one of said compounds and a pharmaceutical diluent or carrier. The compounds are 5-hydroxytryptamine antagonists.
公开号:SU1192618A3
申请号:SU823450275
申请日:1982-06-08
公开日:1985-11-15
发明作者:Поль Блэкберн Томас；Кокс Барри；Джон Гуилфорд Аллэн；Джеймс Ля Конт Дэвид；Джеймс Пирц Роберт；Виллард Торнбер Крейг
申请人:Империал Кемикал Индастриз Лтд (Фирма)；
IPC主号:

专利说明:

one ,. This invention relates to a method for producing new quinoline derivatives which have activity as an antagonist of 5 hydroxytermine for warm-blooded animals. The purpose of the invention is the synthesis of new compounds with valuable properties. Example 1. 2-Dimetsch1aminoethanethiol hydrochloride (58.40 g at 80 wt.% Was added to a suspension of sodium hydride (31.68 g of dispersion at a 50% weight ratio in inorganic oil) and dimethylform-gmide (.-00 ml ) at a temperature of 0-5,. When complete removal of hydrogen was made, a solution of 2-hl () p-.3-fensch1 quinoline (72.70 g) and dimethylformamide (100 mp) was added, the resulting smeg was stirred at 75 for 5 h. After this, the reaction mixture was drunk in ice water (4000 ml) and extracted with ethyl acetate (6 X 500 ml). The ethyl acetate extract was washed successively with water (1000 ml) and brine (1000 ml), and then dried (MgSO4). The ethyl acetate solution was distilled off, and the remaining oil was chromatographed on basic alumina 182 (1200 G, Brockman grade III), eluting with chloroform concentrations in petroleum ether. Eluate obtained at a 10% volume ratio of chloroform in petroleum ether was distilled off. The remaining solid was dissolved in ethanol (800 ml and treated with concentrated hydrochloric acid (25.5 mp). The ethanol was distilled off and the oily residue was azene., Sprinkled with toluene. The solid thus obtained was recrystallized from a mixture of ethanol-diethyl ether and then washed with a small volume of cold acetone. The mixture was filtered, whereby a solid residue was obtained, corresponding to the 1st 2- (2-dimethylaminostil thio) -3-phenylquinoline hydrochloride with a melting point of 195-8. Example s 2-24. The method described in Example 1 was repeated using an equivalent amount of the corresponding 2-chloroquinoline derivatives as a starting material, the salts obtained by addition of an acid were prepared in a standard way, and the following compounds were obtained (see Table 1). Table I .R.
pF (CHP CH, CHj HH Chlorohydrate 1/4
p-CH, (CH, CH, NN Chlorohydrate
o-och, (CH) CH, CK, HH - o-USC (CK), Sour oxalat
H (CH2) g SI, CH NOSN Dichlorohydrate
(CHj) CH, CH Sour oxalate
H
(CHj) CH, SKZ
H
(СН) 2 СН, SI, НСЬЦ
H
(sire ,, sn, h vg H
198-201
165-6
214-6
164
84-5
176-8
174-5
210-2
216-8
Examples 25-32. Using a method similar to example 1, and an equivalent amount of Correspondence. Table 1
raw materials were obtained, the following compounds Gsm,
.tables 2}. .
table 2
In tab. 3 shows the data of elementary analysis and NMR of the compounds obtained by the proposed method, and the data of biological tests.
tabl. 2
The following notation is used in the table: H - found; B - calculated; g - duplicate; m - multiplet; to the quartet; c - singlet; m - triplet.
Table 3
Continuation of table 3
(9H)
67.7 7.0
31
Continuation of table 3
4.06 m (1H) 7.6 s (5H) 7.82 m (5U
1.4s (6H) 2.8s (bN)
7.7.
eleven
67.6 6.7 Below are the results of biological tests. Test 1. Inhibition of head spasms caused in smaller 5-hydroxytryptophan. This test in vivo compounds as 5 hydroxytryptophan (5-HT) at 5-HT central receptors. The test involves the injection of a 5-HT precursor mouse, i.e. 5-hydrotryptophane (5-NTR) The resulting high levels of 5-HT produced in the brain are responsible for the spontaneous convulsions of the head and ears observed in the period after the injection of 5-ttTP. All known 5-HT antagonists of the central action inhibit the convulsive response depending on the dose. The dose range of the test compound was administered intraperitoneally to a male mouse (average weight 18-20 g; groups of 5) 15 minutes before intraperitoneal injection of 5-HTP at 30 mg / kg. Then the mouse is observed after 15 min on head cramps. Non-specific inhibition of a reaction caused, for example, by sedation, is excluded by determining the presence or absence of auricle reflex to tactile stimulation of the ear. In the data below, obtained during this test, special designations are given: if the compound was active, for example at 50 mg / kg, but not active, for example, at 10 mg / kg: A50 HA10
1192618
12 Continuation of table 3
3.93 s (2H) 7.5s (5H) 7.77m (5H) if the compound was active at a dose of less than 10 mg / kg, the LD value. given in mg / kg. Test 2. Antagonism of fenfluramine-induced hyperthermia in rats. This is a sensitive test in vivo, based on the ability of fenfluramine to release 5-HT from endogenous neutron stocks. Female rats (of the biological race Alderley Park, 180–220 g) were placed (5 per cage) in a relatively warm environment (25–28 ° C) 1 hour before the test, with the aim of acclimatization. At the end of the acclimatization period, the rectal temperature of the animals was measured, and the data of this temperature served as the control from which all changes were calculated. To record the control temperatures (1 h, the vehicle compound (distilled water) was orally or subcutaneously tested) and the rectal temperature of each rat was measured after one more hour (O h). Then a dose of fenfluramine or distilled water (control) was injected 15 mg / kg. Then the rectal temperature is measured at the next time after administration of fenfluramine or distilled water: 30 min and 1-6 h. The following tables show the results obtained with this test: if the compound was active, for example measures at a dose of 50 mg / kg, but not active at 10 mg / kg: A50 NA10 if the compound was active; at a dose of less than 10 mg / kg, the LD value is given in mg / kg. The results obtained in tests with the known compound 2 - (2-diethylaminethoxy) -3-phenylquinolinone was as follows: Test 1 Test 2 A 50 NA 50 NA 10 The results obtained in the above tests with a representative selection of products of the proposed method were as follows: Table 4
(skr (snr,
(SNg) 2
(snr
l
(CH,) CH (CH,) CHz
(snr.
l
(CH) d (CHj)
(sn,) (snr,
yenil
(CH,) ;, CCH,) g or
(CH) g
(CH) (CH,)
1.6
2.0
tetil
Methyl - - 2.9 1.7 II „1.9 A, 2 4.6 .2 0.6 2.3
 - 8.3
A 50 NA 10
A 25
1.5
Methyl
atil na 10
A 50
5.9
methyl ethyl NA 10

NA 50
9.1
II
A 50
A 50
NA 10 NA 10
- -
0.5
5.3 II
10.7 1.2 II
7,8
A 50 NA 10
3.0
A 50
NA 10
II
  ".
1.9
7.9 and - -
A 50 9.9 NA 10
Continuation of table 4
7119261818
The above results for the bioelectric method provide the advantage of alkaline tests that show that, compared to the above-mentioned compounds, prepared by known compounds.

权利要求:
Claims (1)
[1]
A method of producing quinoline derivatives of the general formula where A is a radical - (CH ₂ ) _g , which optionally may be substituted with one or two methyl radicals;
R (is a phenyl radical, which optionally may be substituted by a halogen atom or hydroxy, methyl, (1-ZC) alkoxy, methylthio or cyano radical,
R _{ and C may be the same or different and correspond to methyl or ethyl radicals, and one of R ₄ and Ry is hydrogen, and the other is hydrogen, a halogen atom or a methyl or (1-ZC) alkoxy radical, or their pharmaceutically acceptable salts acids, characterized in that the compound of the general formula where Hal is a halogen atom, R _f ·, R ^ h R _} have the indicated meanings, are reacted with the compound of the general formula hs-a-nr ² r ', where A, RgH R ₃ have the indicated values or its salt, obtained by joining
SU <.., 1192618, in the presence of an acid-binding reagent with the isolation of the target product in free form or in the form of a salt.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1192618A3|1985-11-15|Method of producing quinoline derivatives or their pharmaceutically acceptable salts of acids

---

US5246944A|1993-09-21|Quinoline angiotensin ii antagonists incorporating a substituted benzyl element

---

EP0470795A1|1992-02-12|Process for the manufacture of nitriles

---

IE44613B1|1982-01-27|2-piperazinyl-6,7-dimethoxyquinazolines

---

EP0633260B1|2001-11-07|2,3-Dihydro-1,4-benzodioxan-5-yl-piperazine derivatives having 5-HT1A-antagonistic activity

---

US4607039A|1986-08-19|Quinoline derivatives which are 5-hydroxytryptamine antagonists

---

AU617988B2|1991-12-12|Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds

---

EP0156331B1|1989-05-31|Benzofuran derivatives, processes for preparing the same and antihypertensive agents containing the same

---

IE56652B1|1991-10-23|Antihypertensive n-piperazinylalkanoylanilides

---

EP0051321A1|1982-05-12|Cis-dimethylpiperazines for the preparation of N-substituted carbazoles

---

US4788202A|1988-11-29|Sulphonamide derivatives as α2 -adrenoceptor antagonists

---

SU428602A3|1974-05-15|METHOD OF OBTAINING BASIC-SUBSTITUTE DERIVATIVES 1

---

EP0313288B1|1992-12-30|Imidazole derivatives, process for their preparation and their use as alpha 2-adreno-receptor antagonists

---

US4957928A|1990-09-18|Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds

---

US4496737A|1985-01-29|Process for preparing sulfamylamidine antisecretory agents

---

CS202069B2|1980-12-31|Method of preparing 2-/4-substituted piperazine-1-yl/-4-amino-6,7-dimethoxyquinazolines

---

AU629224B2|1992-10-01|Alpha-adrenergic receptor antagonists

---

US4677108A|1987-06-30|4-oxo-pyrido[2,3-d]pyrimidinone derivatives

---

US3957785A|1976-05-18|Bβ-Pyrimidino-aminomethyl-10α-ergoline and 10α-methoxyergoline derivatives

---

EP0091198B1|1987-05-13|Quinoline derivatives

---

EP0202950B1|1993-09-29|Berban derivatives and their preparation and pharmaceutical formulation

---

IL93393A|1994-10-07|Process for the preparation of omicron-carboxypyridyl and omicron-carboxyquinolyl- imidazolinones

---

US4292323A|1981-09-29|Phenyl-1,2,3,4-tetrahydrocarbazoles and use thereof

---

US4500708A|1985-02-19|Benzothiazine derivatives

---

US4681881A|1987-07-21|5-alkoxy-pyrido[4,3-d]pyrimidine derivatives

同族专利:

---

公开号 | 公开日

---

IE821243L|1982-12-09|

---

DK257782A|1982-12-10|

---

IL65852D0|1982-08-31|

---

ES8401034A1|1983-12-01|

---

YU42905B|1988-12-31|

---

JPH0424349B2|1992-04-24|

---

ZA823586B|1983-03-30|

---

ES525298A0|1985-01-16|

---

PT75024B|1984-05-08|

---

ES519006A0|1984-02-01|

---

AT11534T|1985-02-15|

---

AU8386382A|1982-12-16|

---

ES512960A0|1983-12-01|

---

DE3262122D1|1985-03-14|

---

JPS58965A|1983-01-06|

---

FI77451B|1988-11-30|

---

ES8502688A1|1985-01-16|

---

YU123282A|1985-04-30|

---

EP0066993B1|1985-01-30|

---

IE53064B1|1988-05-25|

---

NO161066C|1989-06-28|

---

IN158970B|1987-02-28|

---

PL135871B1|1985-12-31|

---

CA1189077A|1985-06-18|

---

IL65852A|1986-04-29|

---

NO161066B|1989-03-20|

---

CS425382A2|1984-02-13|

---

GR76452B|1984-08-10|

---

CS238624B2|1985-12-16|

---

ES8402576A1|1984-02-01|

---

US4435405A|1984-03-06|

---

AU556719B2|1986-11-13|

---

EP0066993A1|1982-12-15|

---

DK152428C|1988-08-15|

---

AR230437A1|1984-04-30|

---

DK152428B|1988-02-29|

---

NO821904L|1982-12-10|

---

FI821965A0|1982-06-02|

---

YU43269B|1989-06-30|

---

YU188284A|1985-10-31|

---

FI77451C|1989-03-10|

---

PH18503A|1985-08-02|

---

HU186523B|1985-08-28|

---

PL236836A1|1983-09-12|

---

NZ200878A|1985-02-28|

---

PT75024A|1982-07-01|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

DE1049379B|1959-01-29|Farbenfabriken Bayer Aktiengesellschaft, Leverkusen-Bayerwerk|Process for the preparation of 4 - quinoline compounds|

---

DE430960C|1924-07-11|1926-06-23|J G Farbenindustrie Akt Ges|Process for the preparation of basic ethers of quinoline derivatives|

---

US1572768A|1925-06-26|1926-02-09|Winthrop Chem Co Inc|Pharmaceutical product|

---

US1860286A|1929-05-16|1932-05-24|Soc Of Chemical Ind|Basic ethers of aryl-quinolines|

---

GB1511390A|1975-12-04|1978-05-17|Pfizer Ltd|Imidazolylalkyl sulphide antifungal agents|

---

US4343805A|1978-12-16|1982-08-10|John Wyeth & Brother Limited|Heterocyclic compounds|EP0091198B1|1982-04-07|1987-05-13|Imperial Chemical Industries Plc|Quinoline derivatives|

---

DE3377796D1|1982-05-04|1988-09-29|Ici Plc|Quinoline derivatives|

---

US4585866A|1982-06-09|1986-04-29|Merrell Dow Pharmaceuticals Inc.|Treatment of migraine with substituted tropyl benzoate derivatives|

---

GB8308601D0|1983-03-29|1983-05-05|Ici Plc|Heterocyclic compounds|

---

JPH036882B2|1984-02-09|1991-01-31|Inax Corp|

---

GB8630071D0|1986-12-17|1987-01-28|Glaxo Group Ltd|Medicaments|

---

JP2733511B2|1988-10-22|1998-03-30|日本臓器製薬株式会社|New aminoalkane derivatives|

---

JPH03147803A|1989-11-06|1991-06-24|Tiger Mach Seisakusho:Kk|Manufacture of concrete block having multicolor variable pattern on its surface|

---

US6566361B2|1999-06-30|2003-05-20|Laboratories, Upsa|Azapirone pain treatment|

---

FR2795645B1|1999-06-30|2001-09-21|Union Pharma Scient Appl|NEW PHARMACEUTICAL ASSOCIATION WITH ANALGESIC ACTIVITY|

---

EP1216988A4|1999-09-28|2005-04-20|Nihon Nohyaku Co Ltd|Thioalkylamine derivatives and process for the preparation thereof|

---

FR2810664B1|2000-06-27|2004-12-24|Adir|NOVEL CYCLOPROPANE COMPOUNDS, 1,1 AND 1,2-DISSUBSTITUES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

GB0306604D0|2003-03-21|2003-04-30|Curidium Ltd|Second medical use|

---

WO2008104789A1|2007-02-28|2008-09-04|Thromboserin Limited|Therapeutic compositions|

---

WO2009082268A2|2007-12-21|2009-07-02|Alla Chem, Llc|LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB8117642|1981-06-09|

---